Revolution Medicines Inc (NAS:RVMD)
$ 38.33 0.16 (0.42%) Market Cap: 6.32 Bil Enterprise Value: 4.68 Bil PE Ratio: 0 PB Ratio: 3.65 GF Score: 52/100

Revolution Medicines Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 10:20PM GMT
Release Date Price: $37.21 (-3.53%)
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

All right. Good evening, and thanks for sticking with us for our JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst at the firm. And our next presenting company is Revolution Medicines. And it's my pleasure to welcome CEO, Mark Goldsmith, to tell us a little bit about the company. (Operator Instructions)

With that, Mark, thanks again for sharing some of your time with us.

Mark A. Goldsmith
Revolution Medicines, Inc. - CEO, President & Chairman

Thank you, Eric, for the opportunity to introduce Revolution Medicines.

Slide 2. Revolution Medicines is a clinical-stage precision oncology company focused on large unmet medical needs in RAS-addicted cancers, representing a very significant share of all human cancers. Our science-driven strategy includes targeted therapeutics organized into 2 portfolios: First, our RAS(ON) inhibitors, deriving from an innovative technology platform, are unique compounds that target diverse oncogenic RAS

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot